Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol

Gregory A. Yanik; Mary M. Horowitz; Daniel J. Weisdorf; Brent R. Logan; Vincent T. Ho; Robert J. Soiffer; Shelly L. Carter; Juan Wu; John R. Wingard; Nancy L. Difronzo; James L. Ferrara; Sergio Giralt; David K. Madtes; Rebecca Drexler; Eric S. White; Kenneth R. Cooke

doi:10.1016/j.bbmt.2014.02.026

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2014.02.026 ◽

2014 ◽

Vol 20 (6) ◽

pp. 858-864 ◽

Cited By ~ 43

Author(s):

Gregory A. Yanik ◽

Mary M. Horowitz ◽

Daniel J. Weisdorf ◽

Brent R. Logan ◽

Vincent T. Ho ◽

...

Keyword(s):

Clinical Trials ◽

Tumor Necrosis ◽

Controlled Trial ◽

Tumor Necrosis Factor Receptor ◽

Marrow Transplant ◽

Double Blind ◽

Idiopathic Pneumonia Syndrome ◽

Double Blind Placebo ◽

Blood And Marrow Transplant ◽

Necrosis Factor

Download Full-text

Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2012.11.141 ◽

2013 ◽

Vol 19 (2) ◽

pp. S169 ◽

Cited By ~ 4

Author(s):

Gregory Yanik ◽

Vincent T. Ho ◽

Mary Horowitz ◽

Daniel J. Weisdorf ◽

Brent R. Logan ◽

...

Keyword(s):

Stem Cell Transplant ◽

Controlled Trial ◽

Marrow Transplant ◽

Cell Transplant ◽

Tnf Inhibitor ◽

Allogeneic Stem Cell Transplant ◽

Double Blind ◽

Idiopathic Pneumonia Syndrome ◽

Double Blind Placebo ◽

Blood And Marrow Transplant

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine ◽

10.1097/00003246-200103000-00006 ◽

2001 ◽

Vol 29 (3) ◽

pp. 503-510 ◽

Cited By ~ 205

Author(s):

Edward Abraham ◽

Pierre-François Laterre ◽

Jorge Garbino ◽

Susan Pingleton ◽

Thomas Butler ◽

...

Keyword(s):

Septic Shock ◽

Severe Sepsis ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Necrosis Factor

Download Full-text

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Archives of Dermatological Research ◽

10.1007/s00403-019-02024-6 ◽

2019 ◽

Vol 312 (6) ◽

pp. 437-445

Author(s):

Lun-Fei Liu ◽

Ji-Su Chen ◽

Jun Gu ◽

Jin-Hua Xu ◽

Hong-Zhong Jin ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Controlled Trial ◽

Human Tumor ◽

Chinese Patients ◽

Human Tumor Necrosis Factor ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.40753 ◽

2019 ◽

Vol 71 (4) ◽

pp. 599-611 ◽

Cited By ~ 54

Author(s):

Atul Deodhar ◽

Denis Poddubnyy ◽

Cesar Pacheco‐Tena ◽

Carlo Salvarani ◽

Eric Lespessailles ◽

...

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease

Clinical Medicine Insights Gastroenterology ◽

10.4137/cgast.s7613 ◽

2012 ◽

Vol 5 ◽

pp. CGast.S7613 ◽

Cited By ~ 2

Author(s):

Wojciech Blonski ◽

Anna M. Buchner ◽

Gary R. Lichtenstein

Keyword(s):

Tumor Necrosis ◽

Maintenance Treatment ◽

Patient Adherence ◽

Certolizumab Pegol ◽

Controlled Trials ◽

Double Blind ◽

Double Blind Placebo ◽

The Us ◽

Necrosis Factor ◽

Adherence To Therapy

Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNFα antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNFα antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNFα antibodies in patients with CD.

Download Full-text

DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR IN TREATMENT OF SEPTIC SHOCK.

The Pediatric Infectious Disease Journal ◽

10.1097/00006454-199808000-00029 ◽

1998 ◽

Vol 17 (8) ◽

pp. 765-766

Author(s):

&NA;

Keyword(s):

Monoclonal Antibody ◽

Septic Shock ◽

Randomized Controlled Trial ◽

Tumor Necrosis ◽

Controlled Trial ◽

Human Tumor ◽

Human Tumor Necrosis Factor ◽

Double Blind ◽

Randomized Controlled ◽

Necrosis Factor

Download Full-text

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽

Necrosis Factor

Download Full-text

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Circulation ◽

10.1161/01.cir.0000077913.60364.d2 ◽

2003 ◽

Vol 107 (25) ◽

pp. 3133-3140 ◽

Cited By ~ 932

Author(s):

Eugene S. Chung ◽

Milton Packer ◽

Kim Hung Lo ◽

Adedigbo A. Fasanmade ◽

James T. Willerson

Keyword(s):

Heart Failure ◽

Monoclonal Antibody ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Pilot Trial ◽

Severe Heart Failure ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text